Login to Your Account



AAN Roundup


Friday, March 22, 2013
• BrainStorm Cell Therapeutics Inc., of New York, reported some of the final results from a clinical study evaluating its NurOwn technology in 12 amyotrophic lateral sclerosis (ALS) patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription